Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study

Eva Culakova, Ramya Thota, Marek S Poniewierski, Nicole M Kuderer, Adane F Wogu, David C Dale, Jeffrey Crawford, Gary H Lyman, Eva Culakova, Ramya Thota, Marek S Poniewierski, Nicole M Kuderer, Adane F Wogu, David C Dale, Jeffrey Crawford, Gary H Lyman

Abstract

Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapy-associated with considerable morbidity, mortality, and cost. Risk of the initial neutropenic event is greatest during the first cycle. The purpose of this study was to better understand timing of neutropenic events in relation to delivered chemotherapy dose intensity and utilization of supportive care during cancer treatment. A prospective cohort study of adult patients with solid tumors or lymphoma initiating chemotherapy was conducted at 115 randomly selected US practice sites between 2002 and 2006. Chemotherapy-associated toxicities were captured in up to four treatment cycles including severe neutropenia, febrile neutropenia, and infection. Documented interventions included colony-stimulating factor (CSF), antibiotics use, and reductions in chemotherapy relative dose intensity (RDI). A total of 3638 patients with breast (39.7%), lung (23.7%), colorectal (13.6%), ovarian (8.3%) cancers, or lymphoma (14.7%) were eligible for this analysis. The majority of neutropenic and infection events occurred in the first cycle. A significant inverse relationship was observed between reductions in neutropenic and infectious events and increased utilization of measures to reduce these complications in subsequent cycles. More than 60% of patients with stage IV solid tumors underwent reductions in RDI. Patients with lymphoma and stage I-III solid tumors had less dose reductions while receiving more prophylactic CSFs. Approximately, 15% of patients received prophylactic antibiotics. While the risk of neutropenic complications remains greatest during the initial cycle of chemotherapy, subsequently instituted clinical measures in efforts to reduce the risk of these events vary with cancer type and stage.

Keywords: Chemotherapy; infection; neutropenia; toxicity.

© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Cycle-specific neutropenic and infection events during chemotherapy treatment cycles for all patients (A) and among lymphoma (B), early stage (C), or late stage solid tumor (D) patients.
Figure 2
Figure 2
Cumulative use of prophylactic growth factor and antibiotics initiated by a specific cycle for all patients (A) and among lymphoma (B), early stage (C), or late stage solid tumor (D) patients.
Figure 3
Figure 3
Neutropenic events versus supportive measures implemented. Data are presented for all patients together (A) and stratified by lymphoma (B), early stage (C), or late stage (D) solid tumor patients.
Figure 4
Figure 4
Reason for not completing full four cycles of chemotherapy.
Figure 5
Figure 5
Early mortality events due to disease progression or other reasons such as treatment complications.

References

    1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266.
    1. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J. Clin. 2011;61:287–314.
    1. Klastersky JA, Paesmans M. Treatment of febrile neutropenia is expensive: prevention is the answer. Onkologie. 2011;34:226–228.
    1. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J. Clin. Oncol. 2011;29:3984–3989.
    1. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin. Drug Investig. 2007;27:381–396.
    1. Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J. Manag. Care Pharm. 2009;15:669–682.
    1. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl. Compr. Canc. Netw. 2008;6:109–118.
    1. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2005;23:1178–1184.
    1. Gomez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J. Clin. Oncol. 1998;16:2065–2069.
    1. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk. Lymphoma. 2003;44:2069–2076.
    1. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–2409.
    1. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J. Clin. Oncol. 1998;16:2392–2400.
    1. Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J. Clin. Oncol. 1998;16:2700–2707.
    1. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007;12:484–494.
    1. Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J. Clin. Oncol. 2013;31:4290–4296.
    1. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 1991;325:164–170.
    1. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J. Clin. Oncol. 2007;25:3158–3167.
    1. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–1424.
    1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer. 2011;47:8–32.
    1. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, et al. Myeloid growth factors. J. Natl. Compr. Canc. Netw. 2011;9:914–932.
    1. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 2006;24:3187–3205.
    1. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit. Rev. Oncol. Hematol. 2011;77:221–240.
    1. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J. Clin. Oncol. 2000;18:395–404.
    1. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003;21:1431–1439.
    1. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633.
    1. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl. Cancer Inst. 1998;90:1205–1211.
    1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995;332:901–906.
    1. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J. Clin. Oncol. 2004;22:4302–4311.
    1. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J. Clin. Oncol. 2003;21:4524–4531.
    1. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention and treatment of cancer-related infections. J. Natl. Compr. Canc. Netw. 2012;10:1412–1445.
    1. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2013;31:794–810.
    1. Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support. Care Cancer. 2011;19:333–341.
    1. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917–1927.
    1. Schwenkglenks M, Bendall KL, Pfeil AM, Szabo Z, Pettengell R. External validation of a risk model of febrile neutropenia occurrence in non-Hodgkin lymphoma patients. Leuk. Lymphoma. 2013;54:2426–2432.
    1. Ziepert M, Schmits R, Trumper L, Pfreundschuh M, Loeffler M. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann. Oncol. 2008;19:752–762.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다